Neta Goldschmidt
Overview
Explore the profile of Neta Goldschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
El-Galaly T, Cheah C, Dahl Bendtsen M, Nowakowski G, Kansara R, Savage K, et al.
Eur J Cancer
. 2018 Feb;
93:57-68.
PMID: 29477102
Purpose: Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data...
32.
Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A, et al.
Eur J Haematol
. 2018 Feb;
100(5):494-501.
PMID: 29453884
Objective: Daratumumab is a promising new antimyeloma agent. We report a single center "real-world" series of multiple myeloma (MM) and amyloidosis (AL) patients treated with daratumumab. Methods: Forty-one patients were...
33.
Pillar N, Bairey O, Goldschmidt N, Fellig Y, Rosenblat Y, Shehtman I, et al.
Oncotarget
. 2017 Nov;
8(49):86020-86030.
PMID: 29156774
Systemic diffuse large B-cell lymphoma (DLBCL) is a potentially curable disease using current regimen of immunochemotherapy. Central nervous system (CNS) relapse is a complication that occurs in approximately 5% of...
34.
Khare D, Goldschmidt N, Bardugo A, Gur-Wahnon D, Ben-Dov I, Avni B
PLoS One
. 2017 Nov;
12(11):e0187722.
PMID: 29131834
Early detection of relapsed lymphoma improves response and survival. Current tools lack power for detection of early relapse, while being cumbersome and expensive. We searched for sensitive biomarkers that precede...
35.
Reddy A, Zhang J, Davis N, Moffitt A, Love C, Waldrop A, et al.
Cell
. 2017 Oct;
171(2):481-494.e15.
PMID: 28985567
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity poses a...
36.
Mei-Zahav M, Blau H, Bruckheimer E, Zur E, Goldschmidt N
J Otolaryngol Head Neck Surg
. 2017 Oct;
46(1):58.
PMID: 28978360
Background: Severe epistaxis is often difficult to control in patients with hereditary hemorrhagic telangiectasia (HHT). Propranolol has been shown to have antiangiogenic properties in vitro and in vivo and is...
37.
Joffe E, Ariela Arad N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, et al.
Hematol Oncol
. 2017 Jun;
36(1):128-135.
PMID: 28639416
Decreased absolute lymphocyte counts (ALCs) following frontline therapy for chronic lymphocytic leukemia may be associated with disease control, even in patients without evidence of minimal residual disease. We studied the...
38.
Barshtein G, Goldschmidt N, Pries A, Zelig O, Arbell D, Yedgar S
Am J Hematol
. 2017 Jun;
92(9):E559-E560.
PMID: 28614898
No abstract available.
39.
Dann E, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, et al.
Br J Haematol
. 2017 Jun;
178(5):709-718.
PMID: 28589704
This multicentre study evaluated 5-year progression-free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was individualized based on initial prognostic factors and positron emission...
40.
Goldschmidt N, Zamir L, Poperno A, Kahan N, Paltiel O
J Am Board Fam Med
. 2017 Jan;
29(6):702-709.
PMID: 28076253
Background: Presenting symptoms of multiple myeloma (MM) are vague and nonspecific. Early detection poses a diagnostic challenge in primary care. We assessed whether clinical and laboratory data could provide early...